German consortium of familial breast and ovarian cancer
The German Consortium of Familial Breast and Ovarian Cancer is an association of 17 university centers in Germany. The German Consortium for Familial Breast and Ovarian Cancer has been funded by the German Cancer Aid Foundation since 1996 .
Tasks and achievements
The 17 centers for hereditary breast and ovarian cancer, which belong to the German Consortium of Familial Breast and Ovarian Cancer, offer advice to those seeking advice with a family history of breast cancer and ovarian cancer . Discussions with specialized human geneticists are just as much a part of the multi-stage process as consultations and examinations by gynecologists . Those affected and those seeking advice should be able to make an independent decision not only for or against the genetic test, but also for or against the various preventive options.
The women who are genetically predisposed to the development of breast cancer and / or ovarian cancer are offered various options after consultation and examination. These range from an intensive early detection and follow-up program to prophylactic operations on the mammary gland and / or ovaries / fallopian tubes .
Familial breast and ovarian cancer
In 1994 and 1995, the two high-risk genes ( breast cancer genes ) BRCA1 and BRCA2 were discovered for hereditary breast and ovarian cancer. Women with a mutation in these genes are most likely to develop the hereditary form of breast cancer. The risk for carriers of the mutated BRCA1 is given as 65%, for carriers of the mutated BRCA2 as 45%.
research
Significant progress is being made in the area of hereditary breast and ovarian cancer. After examining more than 17,000 families for mutations in the two genes BRCA1 and BRCA2 within the centers of the German Consortium of Familial Breast and Ovarian Cancer, women seeking advice are now able to make much more precise statements about genetic and clinical risks than they were 15 years ago. Basically two genetic strains can be distinguished today. Mutations in a highly penetrant gene (monogenic inheritance) are usually heterozygous , i.e. they are only found on one of two gene copies. Highly penetrant (the mutation affects the function of the gene or its product) is associated with a lifelong increase in risk of up to 60% for breast or ovarian cancer.
Despite advances in understanding the hereditary basis of familial breast and ovarian cancer, known hereditary factors such as changes in the BRCA1 and BRCA2 genes can only explain part of all familial cases. More recent data indicate that additional genetic and non-genetic components contribute to the disease in a multifactorial manner and can increase the risk of the disease. The aim of the German Consortium of Familial Breast and Ovarian Cancer is therefore to further break down the diverse architecture of breast and ovarian cancer, to identify new risk factors and their interactions and to make this knowledge usable for patients through personalized risk prediction and risk-adapted cancer prevention do. To achieve these goals, the consortium works closely with international study groups.
Clinical studies
- Lifestyle intervention in women with hereditary breast and ovarian cancer - LIBRE study
funded by the German Cancer Aid Foundation. Funding period 2013 to 2016 - Genotype / phenotype association, hereditary subtypes of breast and ovarian cancer and translation into risk-adapted preventive strategies.
Funded by the German Cancer Aid Foundation. Funding period 2013 to 2016
Centers for familial breast and ovarian cancer in Germany
- Charité University Medicine, Charité Women's Clinic, Berlin
- Gynecological Clinic of the University Hospital Düsseldorf
- Medical Faculty of the TU Dresden , Clinic and Polyclinic for Gynecology and Obstetrics
- University Medicine Göttingen , Breast Center of the University Medical Center Göttingen
- Hannover Medical School
- Institute for Human Genetics of the [Heidelberg University Hospital]
- University Women's Clinic Kiel
- University of Cologne , Center for Familial Breast and Ovarian Cancer
- University Hospital Leipzig
- Klinikum rechts der Isar of the Technical University of Munich - women's clinic
- University Women's Clinic of the Ludwig Maximilian University
- Institute for Human Genetics at the University Hospital Münster
- University of Regensburg , Institute for Human Genetics
- University of Tübingen , Institute for Human Genetics
- Women's clinic and polyclinic at Ulm University
- Institute for Human Genetics at the University of Würzburg
- Institute for Medical Informatics, Statistics and Epidemiology (IMISE), University of Leipzig
- Breast Center Clinic and Polyclinic for Gynecology University Medical Center Hamburg-Eppendorf (UKE)
- Clinic for Gynecology and Obstetrics, Frankfurt University Hospital
Web links
Individual evidence
- ↑ As of January 18, 2017
- ↑ German Cancer Aid
- ^ A. Antoniou, PD Pharoah, S. Narod et al. a .: Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. In: Am J Hum Genet. 2003; 72, pp. 1117-1130. PMID 12677558 .
- ↑ Breast cancer magazine Mamma Mia !, [1] , special edition 2013, article "Mutations, inheritance and disease risks".
- ↑ a b Clinical Studies of the Familial Breast Cancer Consortium ( Memento of the original from January 18, 2017 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. , accessed January 18, 2017
- ↑ charite.de ( Memento of the original from January 18, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. - Retrieved January 16, 2017.
- ↑ uniklinik-duesseldorf.de ( Memento of the original from January 18, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. - Retrieved January 16, 2017.
- ↑ uniklinikum-dresden.de - Retrieved January 18, 2017.
- ↑ University Hospital Göttingen - Accessed December 19, 2017.
- ↑ mh-hannover.de - Retrieved January 18, 2017.
- ↑ klinikum.uni-heidelberg.de - Retrieved on January 17, 2017.
- ↑ www.uksh.de - Retrieved January 17, 2017.
- ↑ familiaerer-brust-und-eierstockkrebs.uk-koeln.de - Retrieved on January 17, 2017
- ↑ Pathology of the University of Cologne - Retrieved on December 19, 2017.
- ↑ Konsortium-brustkrebs.uniklinikum-leipzig.de - Retrieved January 18, 2017.
- ↑ frauenklinik.med.tum.de - Retrieved on December 19, 2017.
- ↑ klinikum.uni-muenchen.de - Retrieved January 17, 2017.
- ↑ Klinikum.uni-muenster.de - Retrieved January 18, 2017.
- ↑ Center for Familial Breast and Ovarian Cancer of the University of Regensburg ( Memento of the original from August 26, 2017 in the Internet Archive ) Info: The archive link has been inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. - Retrieved December 19, 2017.
- ↑ uni-frauenklinik-tuebingen.de - Accessed December 19, 2017.
- ↑ uniklinik-ulm.de ( Memento of the original from January 18, 2017 in the Internet Archive ) Info: The archive link was inserted automatically and has not yet been checked. Please check the original and archive link according to the instructions and then remove this notice. - Retrieved January 18, 2017.
- ↑ humgen.biozentrum.uni-wuerzburg.de - Retrieved on January 18, 2017.
- ↑ imise.uni-leipzig.de - Retrieved January 18, 2017.
- ↑ uke.de - Retrieved January 18, 2017.
- ↑ kgu.de - Retrieved January 18, 2017.
